Med Life S.A. (M) Stock Price, Fundamentals & Analysis

What M does

Med Life S.A. (M) is a private healthcare provider listed on the Bucharest Stock Exchange (BVB) that offers integrated medical services through clinics and hospitals across Romania. The company operates outpatient units and diagnostic imaging centres, provides consultations with general practitioners and specialists, and delivers day hospitalization, surgical treatment, and medical and surgical specialty services. It also offers maternal and child health services, runs a stem cell bank, and provides a wide range of laboratory services including biochemistry, pathological anatomy, molecular biology and genetics, hematology, immunology, microbiology, cytology, and toxicology. In addition, Med Life S.A. offers healthcare packages, dental services, and fitness and wellness facilities through the Sweat Concept network and Sanopass platform, and is involved in building projects, insurance brokerage, rental activities, and the distribution and retail sale of pharmaceutical products in specialized stores. The company was incorporated in 1996 and is headquartered in Bucharest, Romania.

Key numbers explained

• Med Life S.A. has a market capitalisation of 5.45B RON, which represents the total market value of all its outstanding shares.
• The current share price is 10.26 RON, down 0.19% today, with a 52-week range of 7.38 – 14.46 RON and a one-year price increase of 38.9%.
• The trailing P/E ratio of 1,026 compares the share price to the last 12 months' earnings per share of 0.01 RON; a very high P/E often signals that the market is pricing in future growth or that recent earnings are unusually low.
• The forward P/E ratio of 205.2 uses expected future earnings, suggesting the market anticipates a meaningful improvement in profitability.
• Med Life S.A. has a dividend yield of 0% and pays out 0% of its earnings as dividends, meaning it currently retains all earnings rather than distributing them to shareholders.
• The beta of 0.39 indicates the stock tends to be less volatile than the overall market, moving roughly 39% as much as the market in either direction.
• Revenue over the trailing 12 months was 3.34 mld. RON, growing 11.2% year over year, while the profit margin stands at -0.4% and the operating margin at 4.9%.
• The debt-to-equity ratio of 385.3% shows that the company carries a high level of debt relative to shareholders' equity, which is a key measure of financial leverage.

Recent news

Recent headlines reference transactions under Article 19 of Regulation (EU) 596/2014 and an information document regarding the allocation of shares, which typically relate to management transactions and shareholder rights or capital events.

What to watch

Investors tracking Med Life S.A. often monitor the healthcare sector's regulatory environment and reimbursement policies in Romania, as these directly affect service volumes and pricing. The company's capital structure and debt levels are also relevant, given the high debt-to-equity ratio, alongside its ability to convert revenue growth into sustained profitability. Comparisons with peers such as Farmaceutica Remedia SA (RMAH), Biofarm S.A. (BIO), Antibiotice S.A. (ATB), and Ropharma SA (RPH) can provide context on sector valuation and operational benchmarks.

What M does

Key numbers explained

Recent news

What to watch